Nanovibronix Inc is a medical technology company focusing on the development and commercialization of proprietary therapeutic ultrasound devices for a range of healthcare applications. Their innovative products utilize non-invasive ultrasonic technology designed to enhance pain management, promote healing, and improve overall patient care. The company aims to address unmet clinical needs by providing effective and user-friendly solutions that can be integrated into various treatment protocols, enhancing the quality of life for patients while building partnerships with healthcare professionals and institutions. Read More
NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company” or “NanoVibronix”), a medical technology company specializing in non-invasive therapeutic devices, today announced that on April 9, 2025, Nasdaq formally notified the Company that it has evidenced full compliance with all criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price and $2.5 million stockholders’ equity requirements. Accordingly, the previously disclosed Nasdaq listing matter has been closed. Pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor until April 9, 2026.
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company” or “NanoVibronix”), a medical technology company specializing in non-invasive therapeutic devices, today announced the renewal and expansion of its exclusive three-year distribution agreement with Dukehill Healthcare Pty Ltd. (“Dukehill”).
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
NanoVibronix shares are trading higher by 42.8% to $3.15 during Monday's session. The company announced on Friday that it published its UroShield study, which showed positive data.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that an independent health service study of its UroShield® is published in The Australian and New Zealand Continence Journal.
NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 11 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Thursday, March 13, 2025. The Company’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol NAOV and will begin trading on a split-adjusted basis when the market opens on Friday, March 14, 2025. The new CUSIP number for the common stock following the reverse stock split is 63008J702.
NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced the completion of the acquisition of ENvue Medical Holdings Corp. (“ENvue”) (the “Acquisition”), a privately-held, innovative leader in enteral feeding solutions. This strategic transaction will combine the strengths of both companies, creating a platform for growth and expanded market reach in the medical device sector. The Company believes that the Acquisition will strengthen the combined company’s market position in enteral feeding technology and therapeutic medical devices, as ENvue’s proprietary technology aligns with the Company’s commitment to patient safety and advanced medical solutions and the combined company is expected to benefit from a broader commercial platform, enhanced distribution and operational efficiencies.
